Literature DB >> 15726661

Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests.

Armando Tripodi1, Francesco Salerno, Veena Chantarangkul, Marigrazia Clerici, Massimo Cazzaniga, Massimo Primignani, Pier Mannuccio Mannucci.   

Abstract

The role played by coagulation defects in the occurrence of bleeding in cirrhosis is still unclear. This is partly due to the lack of tests that truly reflect the balance of procoagulant and anticoagulant factors in vivo. Conventional coagulation tests such as prothrombin time and activated partial thromboplastin time are inadequate to explore the physiological mechanism regulating thrombin, because they do not allow full activation of the main anticoagulant factor, protein C, whose levels are considerably reduced in cirrhosis. We used a thrombin generation test to investigate the coagulation function in patients with cirrhosis. Thrombin generation measured without thrombomodulin was impaired, which is consistent with the reduced levels of procoagulant factors typically found in cirrhosis. However, when the test was modified by adding thrombomodulin (i.e., the protein C activator operating in vivo), patients generated as much thrombin as controls. Hence, the reduction of procoagulant factors in patients with cirrhosis is compensated by the reduction of anticoagulant factors, thus leaving the coagulation balance unaltered. These findings help clarify the pathophysiology of hemostasis in cirrhosis, suggesting that bleeding is mainly due to the presence of hemodynamic alterations and that conventional coagulation tests are unlikely to reflect the coagulation status of these patients. In conclusion, generation of thrombin is normal in cirrhosis. For a clinical validation of these findings, a prospective clinical trial is warranted where the results of thrombin generation in the presence of thrombomodulin are related to the occurrence of bleeding.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15726661     DOI: 10.1002/hep.20569

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  113 in total

1.  Blood investigations prior to oral surgery for suspected alcohol-induced coagulopathy. Are they necessary?

Authors:  S Quach; A E Brooke; A Clark; S J Ellison
Journal:  Br Dent J       Date:  2015-08-14       Impact factor: 1.626

Review 2.  New insights into the coagulopathy of liver disease and liver transplantation.

Authors:  M Senzolo; P Burra; E Cholongitas; A-K Burroughs
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

Review 3.  [Coagulation management in patients with liver disease].

Authors:  A Bienholz; A Canbay; F H Saner
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-05-05       Impact factor: 0.840

Review 4.  Haemostatic system in inflammatory bowel diseases: new players in gut inflammation.

Authors:  Franco Scaldaferri; Stefano Lancellotti; Marco Pizzoferrato; Raimondo De Cristofaro
Journal:  World J Gastroenterol       Date:  2011-02-07       Impact factor: 5.742

5.  4 Plasma for Therapeutic Use.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

6.  Hepatobiliary quiz (answers)-13 (2015).

Authors:  Sahaj Rathi; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2015-03-21

Review 7.  Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.

Authors:  Jochen Graff; Sebastian Harder
Journal:  Clin Pharmacokinet       Date:  2013-04       Impact factor: 6.447

Review 8.  Role of the blood coagulation cascade in hepatic fibrosis.

Authors:  Asmita Pant; Anna K Kopec; James P Luyendyk
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-05-03       Impact factor: 4.052

Review 9.  Venous thromboembolism in cirrhosis: a review of the literature.

Authors:  Michelle Buresi; Russell Hull; Carla S Coffin
Journal:  Can J Gastroenterol       Date:  2012-12       Impact factor: 3.522

Review 10.  Perioperative management of the bleeding patient.

Authors:  K Ghadimi; J H Levy; I J Welsby
Journal:  Br J Anaesth       Date:  2016-12       Impact factor: 9.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.